TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Faruqi & Faruqi, Llp
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Rezolute, Inc. shares collapsed approximately 85-90% on December 11, 2025, after the company's Phase 3 sunRIZE clinical trial for its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in treating congenital hyperinsulinism. The stock dropped from around $10.94 to an intraday low near $0.90, triggering Nasdaq volatility halts.

Insights
PRMB   neutral

Limited information provided, only mentioned in passing without specific details


RZLT   negative

The company experienced a catastrophic stock price decline of 85-90% due to its lead drug candidate failing to meet primary and secondary endpoints in a Phase 3 clinical trial, representing a major setback for the company's pipeline and investor confidence.